Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Scand Cardiovasc J. 2022 Dec;56(1):187-197. doi: 10.1080/14017431.2022.2095434.
. The appropriate extent of revascularization following primary intervention is unknown. We conducted a systematic review and meta-analysis of residual Syntax score (rSS) to predict the outcomes and provide guide to optimal management of revascularization following primary intervention. . Previously published studies from 2007 to 2020 assessing the prognostic impact of rSS after ACS were included for this meta-analysis. The primary endpoint was defined as the major adverse clinical events (MACE) in multivariable analysis. The risk ratios (RRs) with 95% confidence intervals (CI) were calculated using the RevMan 5.4 software. . A total of 8,157 participants complicated with ACS from 12 clinical studies were included in this analysis. Based on the wide range of rSS studies available, we classified it into two major groups: rSS < 8 and rSS ≥ 8. In multivariate analysis, the rSS was an independent risk marker for MACE [RR = 1.04 (95%CI; 1.00-1.08)], all-cause mortality [RR = 1.05 (1.03-1.07)] and cardiovascular death [RR = 1.05 (1.03-1.07)]. Patients with incomplete revascularization (ICR) showed higher prevalence of MACE along with all-cause mortality, cardiovascular morality, and recurrent myocardial infarction without significant heterogeneity [RR = 1.60 (1.03-1.07), 2.30 (1.57-3.38), 3.57 (2.09-6.10) and 1.70 (1.38-2.09), respectively]. The patients with rSS ≥ 8 presented higher frequency of all-cause mortality [RR = 2.99 (2.18-4.09)], cardiovascular death [RR = 3.32 (2.22-4.95)], and recurrent myocardial infarction [RR = 1.64 (1.34-2.02)]. . The meta-analysis indicated that an rSS value of 8 could be a reasonable cut-off for incomplete revascularization after ACS and is an efficient tool to guide revascularization. In future, detailed research should focus on investigation of the optimal value of the rSS score.
. 对于原发性介入治疗后再血管化的适当范围尚不清楚。我们进行了一项系统评价和荟萃分析,以剩余Syntax 评分(rSS)预测结果,并为原发性介入治疗后再血管化的最佳管理提供指导。. 本荟萃分析纳入了 2007 年至 2020 年期间评估 ACS 后 rSS 预后影响的已发表研究。主要终点是多变量分析中的主要不良临床事件(MACE)。使用 RevMan 5.4 软件计算风险比(RR)及其 95%置信区间(CI)。. 共有 12 项临床研究中的 8157 名 ACS 合并患者纳入本分析。根据 rSS 研究的广泛范围,我们将其分为两组:rSS<8 和 rSS≥8。多变量分析中,rSS 是 MACE [RR=1.04(95%CI;1.00-1.08)]、全因死亡率 [RR=1.05(1.03-1.07)] 和心血管死亡 [RR=1.05(1.03-1.07)]的独立危险因素。不完全血运重建(ICR)患者的 MACE 发生率更高,全因死亡率、心血管死亡率和复发性心肌梗死的发生率更高,但无明显异质性 [RR=1.60(1.03-1.07)、2.30(1.57-3.38)、3.57(2.09-6.10)和 1.70(1.38-2.09)]。rSS≥8 的患者全因死亡率 [RR=2.99(2.18-4.09)]、心血管死亡 [RR=3.32(2.22-4.95)]和复发性心肌梗死 [RR=1.64(1.34-2.02)]的频率更高。. 荟萃分析表明,rSS 值为 8 可能是 ACS 后不完全血运重建的合理截止值,是指导血运重建的有效工具。未来,应详细研究确定 rSS 评分的最佳值。